Molecular Combing to Be Used by NIH’s Scientists as a Tool for Cancer Research and Drug Screening
September 25 2019 - 12:00AM
Business Wire
Regulatory News:
GENOMIC VISION (Paris:GV) (FR0011799907 – GV), a biotechnology
company developing molecular and Artificial Intelligence tools to
control quality and safety of genetically modified genome, announce
the acquisition of the molecular combing platform by the
Developmental Therapeutics Branch at the National Cancer Institute
(NCI) within the NIH based in Bethesda. The FiberComb® and
FiberVision® are going to be used to study the perturbation of the
DNA replication process in cancer cells. Also, the kinetics of the
replication in specific target genes is the goal that will be
achieved by using of the GENOMIC VISION platform FiberVision®.
After several years of use and a technical benchmark versus
other tools for genome analysis, the NIH has now decided to acquire
a full platform.
(https://ccr.cancer.gov/news/inthejournals/itj_Fu;https://ccr.cancer.gov/news/milestones-2019/article/keeping-dna-replication-in-check;https://ccr.cancer.gov/news/article/new-study-characterizes-proteins-role-in-regulating-dna-replication-in-human-cancer-cells)
The molecular combing helps researcher in the Developmental
Therapeutic Branch to find answer for the diverse regulation of the
DNA replication in cancer cells. The unique GV technology allows to
distinguish the kinetics of the replication forks upon drug
treatment or protein modifications. It also allows to visualize how
the replication is maintained in cancer cells by displaying the
origins of replication.
Aaron Bensimon, co-founder and CEO of Genomic Vision
stated: “We are confident that the NIH choose to use Molecular
Combing for its internal research activities and will result in a
better understanding of mechanisms of actions of many drugs. The
use of GV read-out platform (FiberVision®) coupled with specific
Artificial Intelligence algorithms will allow NCI’s researchers to
go faster in their research programs and to lead to precise
conclusions of their different experiments.
NCI scientists do an incredible work in the cancer research. The
work of some of the senior scientists is focused on the DNA
replication kinetics in human cells and the different regulation in
cancer cells (Zhang, Y., Nat. Commun.). Our technology is the most
appropriate tool to promote and improve their research with high
precision and fast results. Indeed, the FiberVision®, and the whole
GENOMIC VISION platform, are the proper tools to bring deep
understanding of the DNA replication kinetics in cancer cells. They
can easily study differences in the forks’ speeds, stability,
symmetry, the distance between the origins or replication or the
firing of new origins and the resection of the forks, even upon
protein modification. The use of all these parameters brings more
details on the function of some proteins in cancer cells.
Furthermore, GENOMIC VISION platform helps to better identify and
discriminate between compounds against these proteins that are
regulated differently in cancer cells.”
ABOUT GENOMIC VISION
Genomic Vision is a biotechnology company developing molecular
and Artificial Intelligence tools to control quality and safety of
genetically modified genome in particular in genome editing
technologies and biomanufacturing processes.
Genomic Vision proprietary molecular tools provide robust
quantitative measurements that are needed to enable high confidence
characterization of DNA alteration in the genome. These tools are
currently use for monitoring DNA replication in cancerous cell, for
early cancer detection and the diagnosis of genetic diseases.
Based near Paris, in Bagneux, the Company has approximately 30
employees. GENOMIC VISION is a public listed company listed in
compartment C of Euronext’s regulated market in Paris (Euronext: GV
- ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
ABOUT THE NCI
The National Cancer Institute (NCI) is part of the National
Institutes of Health (NIH), which is one of 11 agencies that
comprise the Department of Health and Human Services (HHS). NCI,
established under the National Cancer Institute Act of 1937, is the
Federal Government's principal agency for cancer research and
training. The National Cancer Act of 1971 broadened the scope and
responsibilities of NCI and created the National Cancer Program.
Over the years, legislative amendments have maintained NCI
authorities and responsibilities and added new information
dissemination mandates as well as a requirement to assess the
incorporation of state-of-the-art cancer treatments into clinical
practice.
NCI coordinates the National Cancer Program, which conducts and
supports research, training, health information dissemination, and
other programs with respect to the cause, diagnosis, prevention,
and treatment of cancer.
Member of CAC® Mid & Small, CAC® All-Tradable and
EnterNext© PEA-PME 150 indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the reference
document dated March 29, 2019 filed with the AMF under reference
number R19-004, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190924005979/en/
Genomic Vision Aaron Bensimon Co-fondateur et Président
du Directoire Tél. : +33 1 49 08 07 50
investisseurs@genomicvision.com
Ulysse Communication Bruno Arabian Tel.:+33142682970
barabian@ulysse-communication.com
NewCap Investor Relations / Strategic Communications
Dušan Orešanský / Emmanuel Huynh Tél. : +33 1 44 71 94 92
gv@newcap.eu
Genomic Vision (EU:GV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genomic Vision (EU:GV)
Historical Stock Chart
From Apr 2023 to Apr 2024